Pembrolizumab vs Potassium Citrate Anhydrous

## Pembrolizumab vs Potassium Citrate Anhydrous: Overview

This comparison examines the pharmacological differences between **Pembrolizumab** and **Potassium Citrate Anhydrous**.

## Mechanism of Action

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Pembrolizumab — 26 days; Potassium Citrate Anhydrous — N/A.

## Chemical Properties

**Type**: Pembrolizumab — Antibody; Potassium Citrate Anhydrous — Small molecule.